In addition to the prognostic impact of CD8 levels across multiple cancer indications, densities of intratumoral CD8+ T cells are associated with response to anti-PD-1 (pembrolizumab) treatment in melanoma and mismatch repair deficient cancers, including colon cancer [23,24]. The gene discussed is CD8A; the disease is colonic neoplasm.